An observational study in Geographic Mismatch, Short-Term and Major Adverse Cardiovascular Events, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Sohag University · Observational
This study aims to evaluate whether geographic mismatch is an independent predictor of short-term major adverse cardiovascular events following long coronary stent implantation.
Coronary artery disease (CAD) remains one of the leading causes of morbidity and mortality worldwide despite substantial advances in preventive strategies, pharmacological therapy, and coronary revascularization techniques.
Percutaneous coronary intervention (PCI) has become the standard treatment for many patients with obstructive CAD and has significantly improved both short- and long-term clinical outcomes.
Several clinical, angiographic, and procedural factors have been identified as predictors of adverse outcomes following PCI, including advanced age, diabetes mellitus, chronic kidney disease, left ventricular dysfunction, lesion complexity, and total stent length.
Sohag University is the lead sponsor of 1,218 studies on the registry; 627 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This prospective multi-center observational cohort study will be conducted in the Cardiology Department on 650 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with geographic mismatch.
Procedure: Coronary Stent Implantation
Patients without geographic mismatch.
Procedure: Coronary Stent Implantation
Patients undergo percutaneous coronary intervention (PCI) with successful implantation of a drug-eluting stent (DES) measuring ≥38 mm in length
Incidence of Major Adverse Cardiovascular Events
Incidence of Major Adverse Cardiovascular Events (MACE) will be recorded within 30 days post-percutaneous coronary intervention (PCI).
Time frame: 30 days post-percutaneous coronary intervention
Incidence of all-cause mortality
Incidence of all-cause mortality will be recorded within 60 days.
Time frame: 60 days post-percutaneous coronary intervention
Occurrence of myocardial infarction
Number of participants who experience myocardial infarction following the index percutaneous coronary intervention (PCI).
Time frame: 30 days post-percutaneous coronary intervention
Occurrence of target lesion revascularization
umber of participants who undergo repeat revascularization of the target lesion following the index percutaneous coronary intervention (PCI).
Time frame: 30 days post-percutaneous coronary intervention
Occurrence of definite stent thrombosis
Number of participants who experience definite or probable thrombosis of the stent implanted during the index percutaneous coronary intervention (PCI).
Time frame: 30 days post-percutaneous coronary intervention
Hospital readmission
Number of participants who are readmitted to a hospital following discharge from the index percutaneous coronary intervention (PCI) hospitalization.
Time frame: 30 days post-percutaneous coronary intervention
Length of index hospital stay
Duration of the index hospitalization during which percutaneous coronary intervention (PCI) is performed, measured in days.
Time frame: 60 days post-percutaneous coronary intervention
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.